SS
NBRV

Steve Schonfeld’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Steve Schonfeld’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-200
Closed -$410K – 950
2017
Q3 		$410K Buy
+200
New +$469K 0.04% 407

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Steve Schonfeld's NBRV Position: Q4 2017 in Review

Steve Schonfeld sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2017, closing a stake of 200 shares — an estimated $410K sold.

Steve Schonfeld first reported a position in NBRV in Q3 2017 and held it in 1 quarter. The position peaked at $410K in Q3 2017. 45 funds tracked by Wall St. Rank hold NBRV as of Q4 2017.

  • Steve Schonfeld reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2017 after selling out during the quarter.
  • Steve Schonfeld sold 200 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2017, an estimated $410K.
  • Steve Schonfeld first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2017 and held it in 1 quarter.
  • Steve Schonfeld's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $410K in Q3 2017.
  • 45 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2017.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.